Search
soluble guanylate cyclase stimulator
Contraindications:
- of no benifit for treatment of left ventricular diastolic dysfunction [1]
Mechanism of action:
- stimulates activation of guanylate cyclase
Related
guanylyl cyclase activating protein
soluble guanyl cyclase (guanylate cyclase-1)
Specific
praliciguat
vericiguat (Verquvo)
General
metabolic agent (metabolic modifier)
References
- Armstrong PW et al.
Effect of vericiguat vs placebo on quality of life in patients
with heart failure and preserved ejection fraction:
The VITALITY-HFpEF randomized clinical trial.
JAMA 2020 Oct 20; 324:1512.
PMID: 33079152
https://jamanetwork.com/journals/jama/article-abstract/2771900
- Udelson JE et al.
Effect of praliciguat on peak rate of oxygen consumption in patients
with heart failure with preserved ejection fraction: The CAPACITY HFpEF
randomized clinical trial.
JAMA 2020 Oct 20; 324:1522.
PMID: 33079154
https://jamanetwork.com/journals/jama/article-abstract/2771902